Metropolis Healthcare reported a 26% year-on-year increase in profit after tax (PAT) to ₹56.9 crore for the quarter ended June 30, 2026, driven by robust volume growth and significant operating leverage. Revenue from operations expanded 17% to ₹450.2 crore, while EBITDA surged 27% to ₹113.2 crore, reflecting strong underlying demand in the diagnostic sector. The company achieved this growth without implementing price hikes, relying instead on double-digit increases in patient and test volumes, which underscores its ability to capture market share from unorganized players through brand trust and network expansion.

The unaudited consolidated financial results were announced on August 4, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Executive Chairperson Ameera Shah and Managing Director Surendran Chemmenkotil led the disclosure, highlighting that the performance outpaced the company’s internal growth guidance. The filing also included an investor presentation detailing strategic initiatives under "Metropolis 3.0," focusing on technology integration, scientific differentiation, and sustainable profitability.

Financial Performance

Revenue from operations reached ₹450.2 crore in Q1FY27, up from ₹386.1 crore in the corresponding period of the previous year. EBITDA grew faster at 27%, reaching ₹113.2 crore from ₹89.1 crore, leading to an EBITDA margin expansion of 210 basis points to 25.2%. PAT margin also widened by 90 basis points to 12.6%. Other income declined to ₹5.1 crore from ₹7.5 crore, while finance costs increased to ₹8.3 crore from ₹4.6 crore, yet the bottom line remained resilient due to strong operational efficiency.

Operational Drivers

Operational metrics indicated sustained demand across segments. Patient volume grew 10% year-on-year to 3.7 million, while test volume increased by 11% to 7.8 million. Revenue per Patient (RPP) rose 6% to ₹1,219 and Revenue per Test (RPT) improved 5% to ₹575, attributed to a richer test mix and higher contribution from specialized diagnostics. Management noted that revenue growth was achieved without any price increase, highlighting organic volume-driven expansion.

Segment-wise, TruHealth revenue grew 22% to ₹81 crore, constituting 18% of the segment mix. Premium TruHealth packages saw over 50% growth, while radiology-integrated wellness packages increased by more than 40%. Specialty revenue rose 17% to ₹178 crore, accounting for 40% of the mix. B2C revenue expanded 18% to ₹257 crore, driven by brand pull and digital engagement, whereas B2B revenue increased 15% to ₹193 crore due to a broader clinician network.

Geographically, Tier III cities emerged as the fastest-growing markets with revenue increasing around 25% year-on-year. This outpaced growth in Tier II cities (14%) and Tier I cities (11%), signaling successful penetration beyond large metropolitan areas. The company’s service network expanded to 5,003 points, an 8% YoY increase, with 295 new service points added in Q1FY27 despite the rationalization of 318 non-productive centres.

What the Numbers Show

The divergence between revenue growth (17%) and EBITDA growth (27%) highlights significant operating leverage. The 210-basis point expansion in EBITDA margin, coupled with stable RPT improvements, suggests that fixed cost absorption is improving as volumes scale. Furthermore, the disproportionate growth in Tier III cities (25%) compared to Tier I (11%) indicates a structural shift in the company’s revenue base towards lower-competition markets, potentially offering higher long-term returns on investment as these regions mature. The decline in other income and rise in finance costs were fully offset by core operational efficiencies, demonstrating the quality of earnings.

Metropolis Healthcare reported a consolidated net profit of ₹568.83 million for the quarter ended June 30, 2026, up 25.7% from ₹452.45 million in the same period last year. Revenue from operations increased 16.6% year-on-year to ₹4,502.15 million, reflecting continued expansion in its pathology services business. The company’s standalone net profit for the quarter stood at ₹505.83 million, compared to ₹355.82 million in Q1FY25.

The Board of Directors, meeting on August 04, 2026, approved the unaudited standalone and consolidated financial results pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee on the same date and subjected to a limited review by the statutory auditors, B S R & Co. LLP. The Board also noted that the sale and transfer of the External Quality Assessment Services Business to Metropolis Quality Solutions Private Limited, a wholly owned subsidiary, is now expected to take an additional two months beyond the original six-month timeline set in the February 04, 2026 Business Transfer Agreement.

Financial Performance

Consolidated revenue from operations reached ₹4,502.15 million, up from ₹3,860.63 million in Q1FY25. Total expenses rose to ₹3,776.05 million from ₹3,323.49 million in the prior year period. Employee benefits expense, the largest cost component, increased to ₹1,069.76 million from ₹922.79 million. Other expenses stood at ₹1,386.15 million, up from ₹1,193.04 million. The company recorded a profit before tax of ₹777.12 million, compared to ₹612.30 million in Q1FY25.

Standalone revenue from operations was ₹3,722.84 million, up from ₹3,232.69 million in Q1FY25. Standalone profit before tax was ₹663.76 million, compared to ₹473.84 million in the prior year. Basic earnings per share for the consolidated entity were ₹2.73, up from ₹2.17 in Q1FY25.

Operational Updates

The company continues to operate under a single reportable segment: Pathology service. During the quarter, the Nomination and Remuneration Committee approved the grant of 14,236 Restricted Stock Units (RSUs) under the Metropolis Restrictive Stock Unit Plan — 2025 and 2,12,345 Employee Stock Options under the Metropolis Employees Stock Option Plan — 2025. Additionally, 4,200 RSUs were allotted under the Metropolis Restrictive Stock Unit Plan — 2020.

The financial results reflect the impact of three business acquisitions completed in FY25: Dapic Metropolis Healthcare Private Limited (₹346.10 million), Scientific Metropolis Pathology Private Limited (₹645.00 million), and Dr. RS Patil's Ambika Pathology Laboratory (₹170.00 million). These acquisitions have been fully integrated into the consolidated results for Q1FY26.

What the Numbers Show

Revenue growth outpaced expense growth, leading to an expansion in pre-tax margins. Consolidated profit before tax grew 27.0% YoY, slightly higher than the 16.6% revenue growth, indicating operational leverage. However, employee benefits and other expenses saw significant increases, suggesting rising input costs or wage pressures. The delay in the External Quality Assessment Services Business transfer may impact short-term operational efficiency but keeps the business within the consolidated group structure longer than initially planned.